128 related articles for article (PubMed ID: 4540250)
1. (S)-norepinephrine in the tissues of mice and rats given racemic erythro-3,4-dihydroxyphenylserine (DOPS).
Porter CC; Torchiana ML; Stone CA
Life Sci I; 1972 Aug; 11(16):787-95. PubMed ID: 4540250
[No Abstract] [Full Text] [Related]
2. [Synthesis of norepinephrine from 3,4-dihydroxyphenylserine by L-aromatic amino acid decarboxylase of the rat brain and kidneys].
Fujiwara H; Inagaki C; Ikeda Y; Tanaka C
Nihon Yakurigaku Zasshi; 1976 Oct; 72(7):891-8. PubMed ID: 14060
[TBL] [Abstract][Full Text] [Related]
3. Role of catechol structure in the inhibitory effects of D-isomers of amino acids on the decarboxylation of L-5-hydroxytryptophan.
Shikimi T; Inagaki C; Takaori S
Experientia; 1978 Sep; 34(9):1188-9. PubMed ID: 309827
[TBL] [Abstract][Full Text] [Related]
4. The stereoisomers of 3,4-dihydroxyphenylserine as precursors of norepinephrine.
Bartholini J; Constantinidis J; Puig M; Tissot R; Pletscher A
J Pharmacol Exp Ther; 1975 May; 193(2):523-32. PubMed ID: 1142103
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of enzymic decarboxylation of L-threo-3,4-dihydroxyphenylserine using hog renal L-aromatic amino acid decarboxylase.
Inagaki C; Tanaka C
Biochem Pharmacol; 1978 Apr; 27(7):1081-6. PubMed ID: 26357
[No Abstract] [Full Text] [Related]
6. L-Dopa and imipramine: biochemical and behavioral interaction.
Friedman E; Gershon S
Eur J Pharmacol; 1972 May; 18(2):183-8. PubMed ID: 5037381
[No Abstract] [Full Text] [Related]
7. Central hypotensive effect of L-3,4-dihydroxyphenylalanine in the rat.
Henning M; Rubenson A
J Pharm Pharmacol; 1970 Aug; 22(8):553-60. PubMed ID: 4394527
[No Abstract] [Full Text] [Related]
8. Potentiation of effects of L-dopa on conditioned avoidance behavior by inhibition of extracerebral dopa decarboxylase.
Seiden LS; Martin TW
Physiol Behav; 1971 Apr; 6(4):453-8. PubMed ID: 5148757
[No Abstract] [Full Text] [Related]
9. Behavior and biochemical effects of preferentially protecting monoamines in the brain against the action of reserpine.
Butcher LL; Rhodes DL; Yuwiler A
Eur J Pharmacol; 1972 May; 18(2):204-12. PubMed ID: 4537669
[No Abstract] [Full Text] [Related]
10. Aromatic amino acid decarboxylase inhibitors.
Porter CC
Fed Proc; 1971; 30(3):871-6. PubMed ID: 5575298
[No Abstract] [Full Text] [Related]
11. Dopamine, noradrenaline and 5-hydroxy-trytamine in relation to motor activity, fighting and mounting behaviour. II. L-dopa and DL-threo-dihydroxyphenylserine in combination with Ro 4-4602 and parachlorophenylalanine.
Benkert O; Renz A; Matussek N
Neuropharmacology; 1973 Mar; 12(3):187-93. PubMed ID: 4266876
[No Abstract] [Full Text] [Related]
12. Brain DOPA-5-HTP decarboxylase activity after the chronic administration of L-dopa or 5-hydroxy-L-tryptophan in normal and lesioned cats.
Roberge AG; Poirier LJ
Brain Res; 1974 Aug; 76(3):401-12. PubMed ID: 4546739
[No Abstract] [Full Text] [Related]
13. On the identity of DOPA decarboxylase and 5-hydroxytryptophan decarboxylase (immunological titration-aromatic L-amino acid decarboxylase-serotonin-dopamine-norepinephrine).
Christenson JG; Dairman W; Udenfriend S
Proc Natl Acad Sci U S A; 1972 Feb; 69(2):343-7. PubMed ID: 4536745
[TBL] [Abstract][Full Text] [Related]
14. Enzymatic decarboxylation of L-threo-3,4-dihydroxyphenylserine in rat heart.
Ohmura I; Inagaki C; Araki H; Tanaka C
Jpn J Pharmacol; 1978 Oct; 28(5):747-53. PubMed ID: 31501
[TBL] [Abstract][Full Text] [Related]
15. Interaction of DOPA decarboxylase inhibitors with the effect of alpha-methyldopa on blood pressure and tissue monoamines in rats.
Henning M
Acta Pharmacol Toxicol (Copenh); 1969; 27(2):135-48. PubMed ID: 5819569
[No Abstract] [Full Text] [Related]
16. Dopamine, noradrenaline and 5-hydroxy-tryptamine in relation to motor activity, fighting and mounting behavior. I. L-dopa and DL-threo-dihydroxyphenylserine in combination with Ro 4-4602, pargyline and reserpine.
Benkert O; Gluba H; Matussek N
Neuropharmacology; 1973 Mar; 12(3):177-86. PubMed ID: 4735415
[No Abstract] [Full Text] [Related]
17. Homologs of dopa, alpha-methyldopa, and dopamine as potential cardiovascular drugs.
Winn M; Rasmussen R; Minard F; Kyncl J; Plotnikoff N
J Med Chem; 1975 Apr; 18(4):434-7. PubMed ID: 1079053
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
[TBL] [Abstract][Full Text] [Related]
19. Saligenin analogs of l-DOPA and dl-alpha-methyl-DOPA.
Atkinson M; Hartley D; Lunts LH; Ritchie AC
J Med Chem; 1974 Feb; 17(2):248-9. PubMed ID: 4809259
[No Abstract] [Full Text] [Related]
20. Studies on the activity of L-threo-3,4-dihydroxyphenylserine (L-DOPS) as a catecholamine precursor in the brain. Comparison with that of L-dopa.
Kato T; Karai N; Katsuyama M; Nakamura M; Katsube J
Biochem Pharmacol; 1987 Sep; 36(18):3051-7. PubMed ID: 3115271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
